KaloBios Pharmaceuticals, which is developing monoclonal antibodies to treat respiratory diseases and cancer, raised $70 million by offering 8.8 million shares (500,000 more than expected) at $8, the low end of the revised range of $8 to $9. The company will command a market value of $191 million and an enterprise value of $103 million. KaloBios Pharmaceuticals will begin trading on Thursday on the NASDAQ under the symbol KBIO. Leerink Swann was the sole bookrunner on the deal.
